Corcept soars as ovarian cancer drug succeeds late-stage trial

ReutersMar 31, 2025 1:03 PM

Shares of drugmaker Corcept Therapeutics CORT.O soar 91% to $104.69 premarket

CORT says its experimental drug for ovarian cancer in combination with chemotherapy met the main goal of a late-stage trial

Co says the drug, relacorilant, when combined with chemotherapy agent nab-paclitaxel, showed a 30% reduction in disease-progression risk in platinum-resistant ovarian cancer patients, compared to those treated with chemotherapy alone

Platinum-resistant ovarian cancer is a type of ovarian cancer that doesn't responds to platinum-based chemotherapy treatments, which are typically used as a first-line therapy

As of last close, CORT shares rise up 8.4% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

AST SpaceMobile Shares Plunge in Overnight Trading, What Happened? Will It Affect SpaceX?

TradingKey - In the early hours of April 19, AST SpaceMobile’s (ASTS.US) seventh broadband communication satellite, BlueBird 7, launched from Cape Canaveral aboard Blue Origin’s New Glenn rocket. While the rocket’s first stage was successfully recovered, the second stage deployed the satellite into

Is Netflix Still Worth Buying After a 10% Stock Slump? Who Is the Better Investment Compared to Disney?

TradingKey - After the market close on April 16, streaming giant Netflix delivered a seemingly impressive Q1 earnings report: revenue grew 16% year-over-year to $12.25 billion, exceeding the market expectation of $12.17 billion; earnings per share (EPS) reached $1.23, nearly doubling from $0.66 in t

Allbirds Ditches Sneakers and Pivots to AI Computing - Is BIRD Stock Still Worth Buying After a 600% Surge?

TradingKey - Allbirds surged 600% after announcing a full pivot to GPU leasing as NewBird AI. Shares pulled back 30% the next day. Key support $10, targets $13.30 and $15.90.

Nvidia Launches Ising Model Driving Quantum Sector Surge, QUBT vs IONQ, Which Is More Worth Investing In?

TradingKey - Following Nvidia’s launch of the Ising model, the quantum computing sector was rapidly galvanized; however, a company’s own commercialization progress remains the true determinant of its investment value. In comparison, IonQ’s revenue growth and execution capabilities are clearer, while QUBT is in an earlier stage, offering greater potential upside along with higher risk.

Why the Dollar’s Continuous Depreciation Still Fails to Save the Yen? When Will the Yen Strengthen?

TradingKey - As the U.S. Dollar Index continues to pull back from its highs amid easing geopolitical tensions and weakened rate cut expectations, the Japanese yen, instead of strengthening, has persistently hovered around the key psychological level of 160, repeatedly nearing the Japanese authoritie

Featured Tools